Effects of Metoprolol on Periprocedural Myocardial Infarction After Percutaneous Coronary Intervention (Type 4a MI): An Inverse Probability of Treatment Weighting Analysis
Background: Metoprolol is the most used cardiac selective β-blocker and has been recommended as a mainstay drug in the management of acute myocardial infarction (AMI). However, the evidence supporting this regimen in periprocedural myocardial infarction (PMI) is limited.Methods: This study identifie...
Guardado en:
Autores principales: | Duanbin Li, Ya Li, Maoning Lin, Wenjuan Zhang, Guosheng Fu, Zhaoyang Chen, Chongying Jin, Wenbin Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ce6038ee9d6144029ee7446367b6e7da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Five-year report from the Polish national registry on percutaneous coronary interventions with a focus on coronary artery perforations within chronic total occlusions
por: Rafał Januszek, et al.
Publicado: (2020) -
Effect of short-acting b--blockers on heart rate and blood pressure in patients with acute coronary syndrome during percutaneous and coronary intervention
por: L Rasputina, et al.
Publicado: (2021) -
La clasificación de lesiones coronarias de la Society for Cardiac Angiography and Interventions predice mejor el éxito de la angioplastia coronaria que la del American College of Cardiology/American Heart Association
por: Dussaillant,Gastón R, et al.
Publicado: (2001) -
Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality
por: Barywani SB, et al.
Publicado: (2015) -
Periprocedural temporary pacing in primary percutaneous coronary intervention for patients with acute inferior myocardial infarction
por: Hwang YM, et al.
Publicado: (2016)